Yael S. Schiffenbauer
Weizmann Institute of Science
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yael S. Schiffenbauer.
International Journal of Experimental Pathology | 2003
Michal Neeman; Rinat Abramovitch; Yael S. Schiffenbauer; Catherine Tempel
The preovulatory follicle provides a unique physiological example of rapid growth accompanied by neovascularization, two processes that are generally characteristic of pathologies such as wound repair or malignancy. During the hours preceding ovulation, follicular growth is accompanied by elevated levels of messenger RNA for vascular endothelial growth factor (VEGF). Angiogenic activity, mediated by VEGF, is manifested in the peripheral blood vessels surrounding the follicle, that show capillary sprouting and increased vascular permeability. Following ovulation, rapid infiltration of capillaries through the follicular wall is essential for the formation of the corpus luteum. In this review we compare the preovulatory follicle with a popular model of avascular solid tumour growth, namely the multicellular tumour spheroid, in particular the role of hypoxic stress in the regulation of angiogenesis in both systems.
Toxicologic Pathology | 2015
Catherine Tempel-Brami; Yael S. Schiffenbauer; Abraham Nyska; Nati Ezov; Itai Spector; Rinat Abramovitch; Robert R. Maronpot
Magnetic resonance imaging (MRI) is widely used in preclinical research and drug development and is a powerful noninvasive method for assessment of phenotypes and therapeutic efficacy in murine models of disease. In vivo MRI provides an opportunity for longitudinal evaluation of tissue changes and phenotypic expression in experimental animal models. Ex vivo MRI of fixed samples permits a thorough examination of multiple digital slices while leaving the specimen intact for subsequent conventional hematoxylin and eosin (H&E) histology. With the advent of new compact MRI systems that are designed to operate in most conventional labs without the cost, complexity, and infrastructure needs of conventional MRI systems, the possibility of MRI becoming a practical modality is now viable. The purpose of this study was to investigate the capabilities of a new compact, high-performance MRI platform (M2™; Aspect Imaging, Israel) as it relates to preclinical toxicology studies. This overview will provide examples of major organ system pathologies with an emphasis on how compact MRI can serve as an important adjunct to conventional pathology by nondestructively providing 3-dimensional (3-D) digital data sets, detailed morphological insights, and quantitative information. Comparative data using compact MRI for both in vivo and ex vivo are provided as well as validation using conventional H&E.
Neurotoxicology | 2017
Yuval Ramot; Yael S. Schiffenbauer; Netanel Amouyal; Nathan Ezov; Michal Steiner; Michal Izrael; Neta Lavon; Arik Hasson; Michel Revel; Abraham Nyska
&NA; Stem cells are emerging as a promising new treatment modality for a variety of central nervous system disorders. However, their use is hampered by the potential for the development of teratomas and other tumors. Therefore, there is a crucial need for the development of methods for detecting teratomas in preclinical safety studies. The aim of the current study is to assess the ability of a compact Magnetic Resonance Imaging (MRI) system to detect teratoma formation in mice. Five NOD‐SCID mice were injected intrathecally with human embryonic stem cells (hESCs), with two mice serving as controls. In vivo MRI was performed on days 25 and 48, and ex vivo MRI was performed after scheduled euthanization (day 55). MRI results were compared to histopathology findings. Two animals injected with hESCs developed hind‐limb paresis and paralysis, necessitating premature euthanization. MRI examination revealed abnormal pale areas in the spinal cord and brain, which correlated histopathologically with teratomas. This preliminary study shows the efficacy of compact MRI systems in the detection of small teratomas following intrathecal injection of hESCs in a highly sensitive manner. Although these results should be validated in larger studies, they provide further evidence that the use of MRI in longitudinal studies offers a new monitoring strategy for preclinical testing of stem cell applications. HighlightsThe use of stem cells for CNS disorders is expanding, but there is a risk for teratoma formation.It is necessary to develop methods for quick detection of teratomas in preclinical safety studies.MRI allows quick detection of teratomas and provide accurate localization of the tumors.Compact MRI systems can be used in ordinary labs without the complexity of conventional MRI systems.
Toxicologic Pathology | 2017
Ronit Shaltiel-Karyo; Yonit Tsarfati; Anna Rubinski; Eduardo Zawoznik; Irena Weinstock; Mara Nemas; Yael S. Schiffenbauer; Yuval Ramot; Abraham Nyska; Oron Yacoby-Zeevi
Infusion site reactions are common following subcutaneous infusion of drugs. Such reactions can lead to discontinuation of the treatment. Therefore, assessment of such reactions is essential during preclinical safety studies, and magnetic resonance imaging (MRI) can assist in evaluation. Here, in vivo and ex vivo MRI evaluations were used in addition to classical histopathology to assess the infusion site reaction to ND0701, a novel formulation of apomorphine base developed for the treatment of Parkinson’s disease, in comparison to the commercial apomorphine hydrochloride (HCl) formulation. Both formulations, each at two concentrations, were continuously administered subcutaneously for 20 hr to each of 3 male and 3 female domestic pigs. Based on MRI evaluations, there was a gradual decrease in the volume of the subcutaneous lesions over 4 weeks, with smaller lesions and quicker resolution with ND0701 at concentrations 2.5- to 5-fold higher when compared to the commercial apomorphine HCl formulation. Histopathological evaluation of ND0701 revealed only minimal inflammation at the sites of infusion, whereas the commercial apomorphine HCl caused persistent inflammatory reactions and necrosis. This study provides support to the use of MRI in preclinical testing of subcutaneous drugs when evaluating local site reactions.
Toxicological Sciences | 2017
Yuval Ramot; Yael S. Schiffenbauer; Robert R. Maronpot; Abraham Nyska
Practical magnetic resonance imaging for use in investigative and preclinical toxicology studies is now feasible. Newly developed, self-containing imaging systems provide an efficient and cost-effective means to rapidly obtain in vivo and ex vivo magnetic resonance imaging images to improve how we perform toxicology and toxicologic pathology.
Archive | 1998
Michal Neeman; Gila Meir; Catherine Tempel; Yael S. Schiffenbauer; Rinat Abramovitch
The switch of tumors from avascular to the vascular phase and the onset of tumor angiogenesis mark a critical checkpoint in tumor progression. Avascular tumor dormancy can sometimes extend over many years, while upon vascularization, tumors show increased invasiveness, elevated metastatic potential and significantly worse prognosis (Weidner and Folkman, 1996). Regulation of the transition to the vascular phase depends on the balance between the production of promoters and inhibitors of angiogenesis (Hanahan and Folkman, 1996). The goal of our work was to define physiological scenarios which perturb this balance and can thus drive angiogenesis to previously dormant tumors. Such mechanisms that promote angiogenesis may explain epidemiological observations regarding age specific probabilities of certain tumors, environmental effects and the effects of trauma on tumor growth. In order to follow angiogenesis quantitatively, we developed an experimental system that relies on detection of vessel density by magnetic resonance imaging (MRI).
Proceedings of the National Academy of Sciences of the United States of America | 1997
Yael S. Schiffenbauer; Rinat Abramovitch; Gila Meir; Nava Nevo; Michael Holzinger; Ahuva Itin; Eli Keshet; Michal Neeman
Gynecologic Oncology | 2002
Yael S. Schiffenbauer; Gila Meir; Miriam Maoz; Sharona Even-Ram; Rachel Bar-Shavit; Michal Neeman
Cancer Research | 1995
Yael S. Schiffenbauer; Catherine Tempel; Rinat Abramovitch; Gila Meir; Michal Neeman
Magnetic Resonance in Medicine | 1995
Catherine Tempel; Yael S. Schiffenbauer; Gila Meir; Michal Neeman